Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin in HER2-low Advanced Breast Cancer
NCT05831878Recruiting
- Sponsor
- Renji Hospital
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Open-label, single-arm trial of disitamab vedotin in breast cancer, sponsored by Renji Hospital. Primary endpoint: Objective Response Rate at 1 year. Started May 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05831878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831878.